Naveris is a technology company.
Naveris has raised $33.0M across 1 funding round.
Naveris has raised $33.0M in total across 1 funding round.
Naveris is a biotechnology company developing and commercializing highly sensitive liquid biopsy blood tests for early detection, monitoring, and recurrence surveillance of viral-associated cancers, particularly those linked to Human Papillomavirus (HPV).[1][3][5] Its flagship product, NavDx, detects HPV-related head and neck cancers by analyzing tumor-tissue-modified viral HPV particles in plasma cell-free DNA (cfDNA) using digital droplet PCR, offering greater sensitivity than standard ctDNA tests and enabling earlier identification than imaging.[1][3] Naveris serves cancer centers across the U.S. through its CLIA-certified lab, addressing the problem of late-stage diagnosis in HPV-driven cancers like head and neck, anal, and gynecologic types by providing non-invasive, real-time monitoring for patients post-treatment.[1][2][3] Recent expansions include NavDx+Gyn for gynecologic cancers and NavDx for anal cancer surveillance, bolstered by $51M in funding and CMS Advanced Diagnostic Laboratory Test (ADLT) designation.[1][2]
Naveris was founded in 2017 as a spin-off from the University of North Carolina, leveraging proprietary liquid biopsy technology for cancer-associated DNA analysis.[1][2] Co-founder and CEO Piyush Gupta, alongside Chief Scientific Officer Phil Stephens, leads the Waltham, MA-based company (with facilities in Durham, NC).[2][5] The idea emerged from research advancing early detection of virus-related cancers, starting with NavDx for HPV-associated head and neck cancers, where clinical studies demonstrated its ability to predict recurrence months ahead of imaging.[1][3] Early traction included CLIA lab operations, multicenter studies, and pivotal milestones like the 2024 CMS ADLT status, Phase II clinical trials for molecular residual disease (MRD), and launches of expanded tests amid $51M fundraising.[1][2]
Naveris stands out in liquid biopsy through these key strengths:
Naveris rides the liquid biopsy revolution in precision oncology, capitalizing on rising demand for non-invasive cancer diagnostics amid growing HPV-cancer incidence (e.g., head & neck cases doubling in recent decades).[1][3] Timing aligns with regulatory tailwinds like CMS ADLT designation and expanding evidence from ASCO/ASCO-related studies, amid market forces favoring viral-cancer focus—HPV vaccines reduce incidence but survivors need surveillance tools.[1][2] By enabling earlier intervention, Naveris influences the ecosystem through real-world data registries like NAVigate-HPV, accelerating research in MRD and multi-cancer early detection while competing in a $10B+ liquid biopsy market projected to grow with biotech funding.[1][2][3]
Naveris is poised for expansion with Phase II MRD trials, new test launches, and reimbursement momentum driving adoption in oncology clinics.[2] Trends like AI-enhanced sequencing and multi-omics integration will amplify its sensitivity edge, potentially extending to other viral cancers (e.g., EBV). Influence may evolve via partnerships or IPO, transforming it from HPV specialist to leader in viral-oncology liquid biopsies—ultimately shifting paradigms from reactive imaging to proactive blood-based monitoring, as pioneered by NavDx.[1][2][3]
Naveris has raised $33.0M in total across 1 funding round.
Naveris's investors include Cofounders Capital, F-Prime Capital Partners, Omega Funds, venBio.
Naveris has raised $33.0M across 1 funding round. Most recently, it raised $33.0M Series A in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $33.0M Series A | Cofounders Capital, F-Prime Capital Partners, Omega Funds, venBio |